三生制药:核心品种稳健增长 创新管线迈入收获期

华源证券
17 Feb

投资要点:国内生物制药领军企业,全面提速创新药布局。三生制药成立于1993 年,并于2015 年在香港联交所上市。目前公司已有40 余种上市产品,覆盖肾科、肿瘤科、自身免疫性疾病、眼科及皮肤科等多种治疗领域,其中核心品种特比澳、蔓迪系列等有望持续稳健增长。公司在研管线丰富,拥有IL-17、IL-4R 等最具竞争力的自免管线,PD-1/VEGF 双抗等创新管线亦有积极进展,正在核心优势领域全面打造...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10